Nanoparticle-Delivered Transforming Growth Factor-β1 siRNA Induces PD-1 against Gastric Cancer by Transforming the Phenotype of the Tumor Immune Microenvironment

Fenglei Wu, Xiujuan Xu, Wěi Li, Yidong Hong, Huan Sheng Lai, Jingzhou Zhang, Xueyu Wu, Kangjie Zhou, Nan HuPharmaceuticals 2022 · DOI

TL;DR

This paper presents a novel nanoparticle-based drug delivery system that combines an anti-PD-L1 antibody with TGF-β1 siRNA to reprogram the tumor microenvironment in gastric cancer. This approach effectively shifts the immune landscape from "immune-excluded" to "immune-inflamed," leading to enhanced anti-tumor immunity and tumor shrinkage.

What Problem Does This Paper Address?

Gastric cancer (GC) remains a significant health challenge, with advanced stages often having poor prognoses despite current treatments. Immunotherapy, particularly immune checkpoint blockade (ICB) targeting PD-1/PD-L1, has shown promise but is not universally effective. A key challenge is the "immune-excluded" phenotype of many tumors, where immune cells are kept out of the tumor microenvironment (TME). This phenotype is often associated with high levels of Transforming Growth Factor-beta 1 (TGF-β1), which suppresses anti-tumor immunity. The authors aim to overcome this by developing a dual-action therapeutic that not only blocks PD-L1 but also downregulates TGF-β1, thereby converting the TME to an "immune-inflamed" state that is more receptive to ICB therapy.

Methods

The core of this research is the development of a sophisticated nanoparticle system.

  • Nanoparticle Synthesis: Poly(ethylene glycol)-poly(ε-caprolactone) (PEG-PCL) copolymers were synthesized and then functionalized with an anti-PD-L1 (αPDL1) antibody. This αPDL1-conjugated PEG-PCL was then used to encapsulate TGF-β1 siRNA via a double-emulsion solvent evaporation method, creating siTGF-β1-αPDL1-PEG-PCL nanoparticles.
  • Characterization: The nanoparticles were characterized for their size, polydispersity, zeta potential, morphology (TEM), and the successful conjugation of the αPDL1 antibody (XPS).
  • In Vitro Studies: The stability of the nanoparticles in serum and their drug release profiles were assessed. Cellular uptake studies were performed using fluorescently labeled nanoparticles and siRNA in gastric cancer cell lines (MFC and MKN45) to demonstrate targeted delivery and internalization. Western blot analysis was used to confirm the expression levels of PD-L1 and TGF-β1 in different cell lines.
  • In Vivo Studies: A mouse model of gastric cancer (MFC cells engrafted in mice) was used to evaluate the therapeutic efficacy of the nanoparticles. Various treatment groups were established, including saline control, nanoparticles alone, αPDL1 alone, siTGF-β1 alone, and combinations thereof. Tumor growth was monitored, and post-treatment tumor tissues were analyzed using immunohistochemistry to assess CD8+ T cell infiltration and TGF-β1 expression.
  • Clinical Correlation: The study also included a retrospective analysis of human gastric cancer tissues to correlate immune phenotypes (immune-inflamed, immune-excluded, immune-desert) with TGF-β1 expression.

Datasets

  • Cell Lines: Mouse forestomach carcinoma (MFC) cells, and human gastric cancer cell lines MKN45 and BGC823 were used for in vitro studies.
  • Animal Model: TGF-β1 + MFC cell-engrafted mice were used for in vivo efficacy studies.
  • Human Tissue Samples: 84 paraffin-embedded tissue samples from patients who underwent gastrectomy were used for retrospective analysis of immune phenotypes and TGF-β1 expression.

Key Insights and Ideas

  • Dual-Action Nanoparticles: The development of a single nanoparticle system that simultaneously delivers an immune checkpoint inhibitor (αPDL1) and a gene-silencing agent (TGF-β1 siRNA) is a significant advancement. This dual-targeting approach addresses multiple barriers to effective immunotherapy.
  • TME Reprogramming: The key insight is that blocking TGF-β1 signaling, in conjunction with PD-L1 blockade, can effectively convert the "immune-excluded" TME to an "immune-inflamed" phenotype. This shift is crucial for enabling T cells to infiltrate and attack the tumor.
  • Targeted Delivery Enhances Efficacy: The αPDL1 conjugation on the nanoparticles not only targets them to PD-L1 expressing cells but also significantly enhances cellular uptake, leading to more efficient delivery of the siRNA payload.
  • Clinical Relevance of Immune Phenotypes: The study highlights the importance of understanding tumor immune phenotypes and their correlation with molecular markers like TGF-β1, providing a rationale for personalized combination therapies.

Key Results

  • Nanoparticle Efficacy: The siTGF-β1-αPDL1-PEG-PCL nanoparticles demonstrated significant tumor growth inhibition in the mouse model, outperforming monotherapies and other combination strategies.
  • TGF-β1 Downregulation: The nanoparticles efficiently reduced TGF-β1 mRNA levels in tumor tissues, confirming the intended gene-silencing effect.
  • Immune Cell Infiltration: Immunohistochemistry revealed a marked increase in CD8+ T cell infiltration into the tumor microenvironment in mice treated with the siTGF-β1-αPDL1-PEG-PCL nanoparticles, indicating a shift towards an inflamed phenotype.
  • Clinical Correlation: Human gastric cancer tissues showed a high prevalence of the immune-excluded phenotype, which was significantly correlated with higher TGF-β1 expression, supporting the therapeutic strategy.
  • Cellular Uptake: Nanoparticles conjugated with αPDL1 showed significantly higher uptake in MFC cells (which express PD-L1) compared to control cells, demonstrating effective targeting.

Limitations and Future Work

  • Preclinical Study: The findings are based on preclinical studies in cell lines and mouse models. Further clinical trials are necessary to validate these results in human patients.
  • Systemic Toxicity: While the study aims to reduce systemic toxicity by targeting the TME, the potential for off-target effects of both αPDL1 and TGF-β1 siRNA needs to be thoroughly investigated in future studies.
  • Long-Term Efficacy and Resistance: The long-term efficacy of this combination therapy and the potential development of resistance mechanisms require further investigation.
  • Broader Application: The authors suggest that this approach of combining immune checkpoint blockade with TGF-β1 signaling inhibition could be broadly applied in the clinic for advanced GC and potentially other cancers with similar immune evasion mechanisms. Future work will focus on further investigating the therapeutic efficacy of siTGF-β1-αPDL1-NPs in gastric cancer and exploring their potential for broader clinical application.

Summary updated

Abstract

Immune checkpoint blockade (ICB) is currently considered to be an important therapeutic method, which obtained FDA approval for clinical use in gastric cancer in 2017. As a new mechanism, it was found that the effect of αPDL1 could be improved by blocking the TGF-β1 signaling pathway, which converts the tumor immune microenvironment from the "immune-excluded phenotype" to the "immune-inflamed phenotype". Based on this phenomenon, this project was designed to prepare TGF-β1-siRNA-loaded PEG-PCL nanoparticles conjugated to αPDL1 (siTGF-β1-αPDL1-PEG-PCL) since we have linked similar antibodies to PEG-PCL previously. Therefore, MFC tumor-engrafted mice were established to simulate the biological characteristics of converting the phenotype of the immune microenvironment, and to study the anti-tumor effect and possible molecular mechanism. In this study, αPDL1 antibody conjugates markedly increased the cell uptake of NPs. The produced αPDL1-PEG-PCL NPs efficiently reduced the amounts of TGF-β1 mRNA in MFC cells, converting the immune microenvironment of MFC tumors engrafted mice from the "immune-excluded phenotype" to the "immune-inflamed phenotype". PDL1-harboring gastric cancer had increased susceptibility to αPDL1. The value of this drug-controlled release system targeting the tumor microenvironment in immune checkpoint therapy of gastric cancer would provide a scientific basis for clinically applying nucleic acid drugs.
BibTeX
@inproceedings{wu2022nanoparticle,
  author = {Fenglei Wu and Xiujuan Xu and Wěi Li and Yidong Hong and Huan Sheng Lai and Jingzhou Zhang and Xueyu Wu and Kangjie Zhou and Nan Hu},
  title = {{Nanoparticle-Delivered Transforming Growth Factor-β1 siRNA Induces PD-1 against Gastric Cancer by Transforming the Phenotype of the Tumor Immune Microenvironment}},
  booktitle = {Pharmaceuticals},
  year = {2022},
  doi = {10.3390/ph15121487},
}
Figure